N. Martin

发表

Pharmacokinetic/Pharmacodynamic Modeling in Drug Development

Jeffrey S. Barrett, J. Barrett, S. Rohatagi, 2004 .

Permeation prediction of M100240 using the parallel artificial membrane permeability assay.

Chengyue Zhu, N. Martin, Lan Jiang, 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Pegylation: a novel process for modifying pharmacokinetics.

J. M. Harris, N. Martin, J M Harris, 2001, Clinical pharmacokinetics.

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies

S. Fishbane, J. Wish, N. Martin, 2019, Kidney medicine.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

M. Stölzel, Jeffrey Frankel, S. Herschorn, 2013, Urology.

Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.

S. Fishbane, W. Wisemandle, Bhupinder Singh, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects.

W. Wisemandle, N. Martin, D. Stalker, 2016, Clinical therapeutics.

Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

S. Zeuzem, K. Nieforth, J. Heathcote, 2001, Expert opinion on investigational drugs.

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease

S. Fishbane, W. Wisemandle, B. Spinowitz, 2019, Kidney international reports.

Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen(®) After Multiple Subcutaneous Doses to Healthy Male Subjects.

N. Martin, D. Stalker, S. Reid, 2016, Clinical therapeutics.

The Effect of Food on the Pharmacokinetics of a Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240

J. Barrett, N. Martin, B. Brennan, 2004, Journal of clinical pharmacology.

Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.

V. Nitti, S. Rosenberg, N. Martin, 2013, The Journal of urology.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

S. Kaplan, J. Klecka, C. Chapple, 2013, European urology.

Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240

J. Barrett, M. Pfister, N. Martin, 2004, Journal of clinical pharmacology.

Optimizing dose selection with computer modeling and simulation: application to the vasopeptidase inhibitor m100240

M. Pfister, N. Martin, L. Haskell, 2004 .

No Clinically Relevant CYP3A Induction with the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240

J. Barrett, S. R. Howell, N. Martin, 2004, Journal of clinical pharmacology.

Site-specific absorption of M100240 and MDL 100,173 in rats evaluated using Sweetana-Grass diffusion chamber technology.

N. Martin, Lan Jiang, K. Hwang, 2002, Journal of pharmacological and toxicological methods.

Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.

V. Nitti, K. Andersson, N. Martin, 2013, The Journal of urology.

Selective b 3 -Adrenoceptor Agonists for the Treatment of Overactive Bladder

V. Nitti, K. Andersson, N. Martin, 2013 .

Fibrin sealant for retinoblastoma: where are we?

D. Abramson, Jonathan W. Kim, N. Martin, 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Weight-Based versus Fixed Dosing of Peginterferon (40kDa) Alfa-2a

N. Martin, Matthew W. Lamb, 2002, The Annals of pharmacotherapy.

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial

M. B. Blauwet, N. Martin, V. Khullar, 2013, BMC Urology.

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

V. Nitti, S. Herschorn, M. B. Blauwet, 2013, International journal of clinical practice.

Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

V. Nitti, S. Herschorn, N. Martin, 2013, The Journal of urology.

Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.

N. Martin, B. Brennan, 2004, Journal of the American Pharmacists Association : JAPhA.

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study

N. Martin, A. Steup, C. Lademacher, 2021, Neurourology and urodynamics.

V. Nitti, S. Herschorn, M. B. Blauwet, 2012 .

885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL

V. Nitti, S. Herschorn, N. Martin, 2011 .

684 Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a prospective, randomised European-Australian phase III trial

M. B. Blauwet, N. Martin, V. Khullar, 2012 .

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

R. Thurston, N. Santoro, G. Neal-Perry, 2023, The Journal of clinical endocrinology and metabolism.

Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers.

R. Lewis, G. Novack, G. Hantsbarger, 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Mass Balance Study of [14C]M100240, a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, in Healthy Male Subjects

B. Jensen, S. Rohatagi, N. Martin, 2003, American journal of therapeutics.

1959 MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME - RESULTS FROM A NORTH-AMERICAN STUDY

V. Nitti, S. Herschorn, M. B. Blauwet, 2011 .

1958 THE SELECTIVE β3-ADRENORECEPTOR AGONIST MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME

V. Nitti, S. Herschorn, N. Martin, 2011 .

M. Stölzel, S. Herschorn, A. Gousse, 2013, Urology.

Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers

J. Barrett, I. Wilding, N. Martin, 2003, Journal of clinical pharmacology.